For the Inventor, By the Inventor

Enter assignee name

Newark, CA, United States of America

Cymabay Therapeutics, Inc.

USPTO Granted Patents = 43

CIPO Patents = 6

EPO Patents = 13

Trademarks = 5

Forward Citations = 116

Loading Chart...

Loading Chart...

39 inventors (with patents filed for the assignee):

Charles A McWherter (32 out of 33 patents)

Brian K Roberts (15 out of 16 patents)

Pol Boudes (13 out of 14 patents)

4. Jiangao Song (10 out of 24 patents)

5. David Brian Karpf (10 out of 16 patents)

6. Xueyan Wang (9 out of 10 patents)

7. Robert Louis Martin (9 out of 9 patents)

8. Yun-Jung Choi (8 out of 9 patents)

9. Brian Edward Lavan (7 out of 8 patents)

10. Xin Chen (7 out of 20 patents)

11. Jingyuan Ma (7 out of 19 patents)

12. Imad Nashashibi (7 out of 16 patents)

13. Gopal Chandra Saha (6 out of 6 patents)

14. Jeffrey D Johnson (5 out of 117 patents)

15. Peng Cheng (5 out of 15 patents)

Core Competencies:

Intrahepatic Cholestatic Diseases

NAFLD

NASH

Hyperuricemia

Gout Treatment

Heterocyclic Receptor Agonists

Oxymethylene Aryl Compounds

Metabolic Disorders

Bicyclic Agonists

Crystalline Solid Forms

Amorphous Forms

DCC Mediated Coupling

43 patents: Sort by Forward Citations

1. 11596614 - Treatment of intrahepatic cholestatic diseases (2023-03-07),

2. 11406611 - Treatment of intrahepatic cholestatic diseases (2022-08-09),

3. 11224580 - Treatment of intrahepatic cholestatic diseases (2022-01-18),

4. 11179359 - Treatment of NAFLD and NASH (2021-11-23),

5. 11007162 - Methods of reducing small, dense LDL particles (2021-05-18),

6. 11000494 - Treatment of intrahepatic cholestatic diseases (2021-05-11),

7. 10828273 - Treatment of intrahepatic cholestatic diseases (2020-11-10),

8. 10813896 - Treatment of intrahepatic cholestatic diseases (2020-10-27),

9. 10813895 - Treatment of intrahepatic cholestatic diseases (2020-10-27),

10. 10722483 - Treatment of NAFLD and NASH (2020-07-28),

11. 10512622 - Treatment of intrahepatic cholestatic diseases (2019-12-24),

12. 10478411 - Treatment of intrahepatic cholestatic diseases (2019-11-19),

13. 10342770 - Treatment of NAFLD and NASH (2019-07-09),

14. 10292983 - Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions (2019-05-21),

15. 10272058 - Treatment of intrahepatic cholestatic diseases (2019-04-30),

CymaBay Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for liver and other chronic diseases with high unmet medical need. They are committed to improving the lives of patients and addressing unmet medical needs through their research and development efforts. With a team of dedicated scientists and professionals, CymaBay is developing breakthrough treatments to make a meaningful impact on patients' lives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

43 Patents

#15 in Newark, CA

#1,845 in California

#7,821 in US

#15,578 in the World

Newark, CA, United States of America

Cymabay Therapeutics, Inc.

Forward Citations = 116

39 inventors:

Charles A McWherter (32 out of 33 patents)

Brian K Roberts (15 out of 16 patents)

Pol Boudes (13 out of 14 patents)

4. Jiangao Song (10 out of 24 patents)

5. David Brian Karpf (10 out of 16 patents)

Please report any incorrect information to support@idiyas.com

Loading…